Free Trial
→ SpaceX eyes a 1.75 trillion valuation - here's what to know (From Brownstone Research) (Ad)tc pixel Free NFX Stock Alerts

Nuformix (NFX) Competitors

Nuformix logo
GBX 0.17 0.00 (0.00%)
As of 05/15/2026 10:37 AM Eastern
Compare

NFX vs. FAB, IXI, RLM, CIZ, and NSCI

Should you buy Nuformix stock or one of its competitors? MarketBeat compares Nuformix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nuformix include Fusion Antibodies (FAB), IXICO (IXI), Realm Therapeutics (RLM), Cizzle Biotechnology (CIZ), and NetScientific (NSCI). These companies are all part of the "biotechnology" industry.

How does Nuformix compare to Fusion Antibodies?

Nuformix (LON:NFX) and Fusion Antibodies (LON:FAB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Nuformix has a beta of 1.545, indicating that its share price is 55% more volatile than the broader market. Comparatively, Fusion Antibodies has a beta of 1.215, indicating that its share price is 22% more volatile than the broader market.

Nuformix has a net margin of 0.00% compared to Fusion Antibodies' net margin of -91.92%. Nuformix's return on equity of -83.53% beat Fusion Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
NuformixN/A -83.53% -17.20%
Fusion Antibodies -91.92%-210.32%-63.78%

In the previous week, Fusion Antibodies had 2 more articles in the media than Nuformix. MarketBeat recorded 2 mentions for Fusion Antibodies and 0 mentions for Nuformix. Fusion Antibodies' average media sentiment score of 1.22 beat Nuformix's score of 0.00 indicating that Fusion Antibodies is being referred to more favorably in the news media.

Company Overall Sentiment
Nuformix Neutral
Fusion Antibodies Positive

0.1% of Nuformix shares are held by institutional investors. Comparatively, 7.6% of Fusion Antibodies shares are held by institutional investors. 9.3% of Nuformix shares are held by company insiders. Comparatively, 5.9% of Fusion Antibodies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Nuformix has higher earnings, but lower revenue than Fusion Antibodies. Fusion Antibodies is trading at a lower price-to-earnings ratio than Nuformix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NuformixN/AN/A-£383.40K-£0.04N/A
Fusion Antibodies£1.60M12.14-£4.10M-£1.50N/A

Summary

Nuformix beats Fusion Antibodies on 8 of the 12 factors compared between the two stocks.

How does Nuformix compare to IXICO?

Nuformix (LON:NFX) and IXICO (LON:IXI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Nuformix has higher earnings, but lower revenue than IXICO. Nuformix is trading at a lower price-to-earnings ratio than IXICO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NuformixN/AN/A-£383.40K-£0.04N/A
IXICO£6.53M2.34-£3.58M-£1.85N/A

0.1% of Nuformix shares are owned by institutional investors. Comparatively, 4.7% of IXICO shares are owned by institutional investors. 9.3% of Nuformix shares are owned by company insiders. Comparatively, 6.0% of IXICO shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, IXICO had 2 more articles in the media than Nuformix. MarketBeat recorded 2 mentions for IXICO and 0 mentions for Nuformix. IXICO's average media sentiment score of 0.17 beat Nuformix's score of 0.00 indicating that IXICO is being referred to more favorably in the news media.

Company Overall Sentiment
Nuformix Neutral
IXICO Neutral

Nuformix has a net margin of 0.00% compared to IXICO's net margin of -25.27%. IXICO's return on equity of -13.74% beat Nuformix's return on equity.

Company Net Margins Return on Equity Return on Assets
NuformixN/A -83.53% -17.20%
IXICO -25.27%-13.74%-10.40%

Nuformix has a beta of 1.545, suggesting that its stock price is 55% more volatile than the broader market. Comparatively, IXICO has a beta of 0.07, suggesting that its stock price is 93% less volatile than the broader market.

Summary

IXICO beats Nuformix on 7 of the 12 factors compared between the two stocks.

How does Nuformix compare to Realm Therapeutics?

Nuformix (LON:NFX) and Realm Therapeutics (LON:RLM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Realm Therapeutics has higher revenue and earnings than Nuformix. Nuformix is trading at a lower price-to-earnings ratio than Realm Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NuformixN/AN/A-£383.40K-£0.04N/A
Realm Therapeutics£501.92K0.00N/A-£17.50N/A

0.1% of Nuformix shares are owned by institutional investors. 9.3% of Nuformix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Nuformix's average media sentiment score of 0.00 equaled Realm Therapeutics'average media sentiment score.

Company Overall Sentiment
Nuformix Neutral
Realm Therapeutics Neutral

Realm Therapeutics' return on equity of 0.00% beat Nuformix's return on equity.

Company Net Margins Return on Equity Return on Assets
NuformixN/A -83.53% -17.20%
Realm Therapeutics N/A N/A N/A

Summary

Realm Therapeutics beats Nuformix on 4 of the 7 factors compared between the two stocks.

How does Nuformix compare to Cizzle Biotechnology?

Nuformix (LON:NFX) and Cizzle Biotechnology (LON:CIZ) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

In the previous week, Nuformix's average media sentiment score of 0.00 equaled Cizzle Biotechnology'saverage media sentiment score.

Company Overall Sentiment
Nuformix Neutral
Cizzle Biotechnology Neutral

Cizzle Biotechnology's return on equity of 104.99% beat Nuformix's return on equity.

Company Net Margins Return on Equity Return on Assets
NuformixN/A -83.53% -17.20%
Cizzle Biotechnology N/A 104.99%-31.72%

0.1% of Nuformix shares are owned by institutional investors. Comparatively, 0.0% of Cizzle Biotechnology shares are owned by institutional investors. 9.3% of Nuformix shares are owned by company insiders. Comparatively, 72.2% of Cizzle Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Nuformix has a beta of 1.545, suggesting that its stock price is 55% more volatile than the broader market. Comparatively, Cizzle Biotechnology has a beta of 0.068073176, suggesting that its stock price is 93% less volatile than the broader market.

Cizzle Biotechnology is trading at a lower price-to-earnings ratio than Nuformix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NuformixN/AN/A-£383.40K-£0.04N/A
Cizzle BiotechnologyN/AN/A-£2.81K-£0.17N/A

Summary

Nuformix beats Cizzle Biotechnology on 5 of the 8 factors compared between the two stocks.

How does Nuformix compare to NetScientific?

NetScientific (LON:NSCI) and Nuformix (LON:NFX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

Nuformix has lower revenue, but higher earnings than NetScientific. Nuformix is trading at a lower price-to-earnings ratio than NetScientific, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NetScientific£1.45M0.00-£2.64M-£0.11N/A
NuformixN/AN/A-£383.40K-£0.04N/A

14.7% of NetScientific shares are held by institutional investors. Comparatively, 0.1% of Nuformix shares are held by institutional investors. 42.4% of NetScientific shares are held by insiders. Comparatively, 9.3% of Nuformix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, NetScientific's average media sentiment score of 0.00 equaled Nuformix'saverage media sentiment score.

Company Overall Sentiment
NetScientific Neutral
Nuformix Neutral

Nuformix has a net margin of 0.00% compared to NetScientific's net margin of -182.91%. NetScientific's return on equity of -13.70% beat Nuformix's return on equity.

Company Net Margins Return on Equity Return on Assets
NetScientific-182.91% -13.70% -9.42%
Nuformix N/A -83.53%-17.20%

NetScientific has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market. Comparatively, Nuformix has a beta of 1.545, indicating that its stock price is 55% more volatile than the broader market.

Summary

NetScientific beats Nuformix on 6 of the 10 factors compared between the two stocks.

Get Nuformix News Delivered to You Automatically

Sign up to receive the latest news and ratings for NFX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NFX vs. The Competition

Export
MetricNuformixBiotechnology IndustryMedical SectorLON Exchange
Market Cap£4.44M£473.11M£6.38B£2.60B
Dividend YieldN/A3.86%2.81%6.15%
P/E Ratio-4.333.8320.66365.91
Price / SalesN/A7,766.09552.3588,030.08
Price / Cash3.5513.1342.4327.89
Price / Book0.3184.219.877.74
Net Income-£383.40K-£96.07M£3.57B£5.89B
7 Day Performance-20.19%0.91%0.23%0.21%
1 Month Performance-5.56%-0.01%-2.54%0.63%
1 Year Performance30.77%68.91%33.54%78.11%

Nuformix Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NFX
Nuformix
N/AGBX 0.17
flat		N/A+30.8%£4.44MN/AN/A3
FAB
Fusion Antibodies
N/AGBX 15
+8.0%		N/A+131.3%£18.75M£1.60MN/A48
IXI
IXICO
N/AGBX 6.60
-0.6%		N/A-24.7%£14.39M£6.53MN/A89
RLM
Realm Therapeutics
N/AN/AN/AN/A£13.41M£501.92KN/AN/A
CIZ
Cizzle Biotechnology
N/AGBX 3.30
+9.3%		N/A+131.4%£13.08MN/AN/A4

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:NFX) was last updated on 5/17/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
SpaceX Goes Public. Here's What Happens To Your IRA.
When SpaceX goes public, fund managers will sell existing portfolio holdings to fund the move. Trillions in as...
Americas Gold Company | Sponsoredtc pixel